MA05.10 Patient-Initiated a Phase II study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutated T790M-Negative NSCLC
Journal of Thoracic Oncology(2023)
摘要
In recent years, with the evolution of personalized medicine, patient advocacy associations for rare fractions have been organized across countries, contributing to the promotion of research. In Japan, 15 patient advocacy associations were initiated in 2015. Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is an established standard treatment option for chemotherapy-naive patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).
更多查看译文
关键词
osimertinib,patient-initiated,m-negative
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要